Table 1

Clinical and functional responses in patients who switched treatments, 3 and 6 months postswitch (as observed)

n/N (%)UPA 15 mg once daily to ADA (N=251)ADA to UPA 15 mg once daily (N=159)
3 months postswitch6 months postswitch3 months postswitch6 months postswitch
DAS28(CRP) ≤3.271/233 (30.5)91/230 (39.6)77/150 (51.3)82/147 (55.8)
DAS28(CRP) <2.634/233 (14.6)49/230 (21.3)45/150 (30.0)51/147 (34.7)
CDAI ≤1074/242 (30.6)95/234 (40.6)58/148 (39.2)77/146 (52.7)
CDAI ≤2.88/242 (3.3)12/234 (5.1)13/148 (8.8)22/146 (15.1)
SDAI ≤1169/231 (29.9)96/229 (41.9)64/144 (44.4)77/145 (53.1)
SDAI ≤3.39/231 (3.9)11/229 (4.8)12/144 (8.3)26/145 (17.9)
Mean change from baseline (95% CI)*
 HAQ-DI−0.56 (−0.64 to −0.48)−0.58 (-0.66 to −0.49)−0.69 (−0.79 to −0.60)−0.73 (−0.83 to −0.63)
 DAS28(CRP)−2.13 (−2.3 to −1.96)−2.40 (−2.58 to −2.22)−2.74 (−2.96 to −2.52)−2.88 (−3.11 to −2.65)
 CDAI−24.94 (−26.86 to −23.01)−27.28 (−29.35 to −25.21)−27.01 (−29.63 to −24.56)−29.47 (−32.23 to −26.71)
 SDAI−25.80 (−27.84 to −23.76)−28.30 (−30.45 to −26.15)−28.57 (−31.31 to −25.84)−31.02 (−33.86 to −28.19)
  • *Mean change from baseline at randomisation.

  • ADA, adalimumab; CDAI, Clinical Disease Activity Index; DAS28(CRP), 28-joint disease activity score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; SDAI, Simplified Disease Activity Index;UPA, upadacitinib.